TY - JOUR
AR - NNB-2018-1-104
TI - Long-term Efficacy and Safety of Donepezil Dose Escalation for Patients with Alzheimer?s Disease in a Clinical Setting
AU -  Laura , Tan
AU - Chathuri J , Yatawara
AU - Debby , Ng
AU - Nagaendran , Kandiah
JO - Neurology and Neurobiology
PY - 2018
DA - Fri 08, Jun 2018
SN - 2613-7828
DO - http://dx.doi.org/10.31487/j.NNB.2018.10.004
UR - https://www.sciencerepository.org/long-term-efficacy-and-safety-of-donepezil-dose-escalation-for-patients-with-alzheimers-disease-in-a-clinical-setting_NNB-1-104 
KW - dementia, Alzheimer’s disease, treatment, efficacy, safety
AB - Background: Donepezil is a routinely prescribed cognitive enhancer for patients with Alzheimer’s disease
(AD), however the effectiveness and safety of long-term high doses remains largely unexplored.
Objective: We investigated the long-term efficacy and safety of Donepezil dose escalation in reducing
global cognitive decline for patients with AD in a clinical setting.
Method: In a naturalistic, open-label, controlled study design, 71 mild to moderate AD patients from a
tertiary clinic were prescribed Donepezil 5mg/day for 12 months (phase 1), while 9 AD patients received
no treatment. Patients who showed limited benefits (N=30) with Donepezil 5mg/day were titrated up to
10mg/day for a subsequent 12 months (phase 2) and the remaining (N=41) patients continued on 5mg/day.
The primary outcome was global cognition, indexed using the Mini-Mental State Examination (MMSE).
Results: Phase 1 trends confirmed Donepezil 5mg/day was better than no treatment at reducing cognitive
decline (p = .09, f=.18). Phase 2 trends indicated that for patients who showed limited response to Donepezil
5mg/day, Donepezil 10mg/day was more effective in reducing slope of cognitive decline (p = 0.13, f= .42).
Additionally, the patients that were titrated up to 10mg/day had comparable treatment benefits to those
patients that remained on 5mg/day during phase 2 (p = .32, f =.12). Side effects in the 10mg/day group were
not significantly different from the side effects in the 5mg group (t (67)=-1.27, p=.21).
Conclusion: Donepezil dose escalation in patients with AD is safe and may result in large noticeable effects
on cognition, with effects comparable to patients who initially responded well to 5mg/day.